CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CIDP drug shows promise in early trial
Disease control CompletedThis phase 2 study tested a drug called SAR445088 in 98 adults with CIDP, a nerve disorder causing weakness and numbness. The trial looked at how well the drug works in people who are on standard treatment, those who don't respond to it, and those who haven't tried it yet. Resear…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: PHASE2 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Blood test may Fine-Tune IVIg dosing for rare nerve disorders
Knowledge-focused CompletedThis study looked at 20 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were starting intravenous immunoglobulin (IVIg) treatment. Researchers measured changes in IgG levels in the blood after the first dose to…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Sponsor: Walton Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC